Phaseline

Companies › Xadcera Biopharmaceutical (Suzhou)

Xadcera Biopharmaceutical (Suzhou): clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DM001–Phase 1Breast NeoplasmsJan 2027
DM002–Phase 1Ovarian NeoplasmsOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06475937DM001Phase 1Breast NeoplasmsOncologyJan 2027
NCT06751329DM002Phase 1Ovarian NeoplasmsOncologyOct 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.